DMAC Insider Trading Activity and SEC Form 4 Filings
DMAC insider trading summary
Over the past 12 months, insiders at DiaMedica Therapeutics Inc. (DMAC) reported 14 open-market purchases worth $15.3M by 2 insiders and no sales on SEC Form 4. Net insider buying was $15.3M.
Latest DMAC insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 25, 2025 | Jan Stahlberg | 10% Owner | Buy | $627K (73,099 @ $8.57) |
| Nov 25, 2025 | Ab Trill | 10% Owner | Buy | $627K (73,099 @ $8.57) |
| Nov 24, 2025 | Jan Stahlberg | 10% Owner | Buy | $318K (40,253 @ $7.89) |
| Nov 24, 2025 | Ab Trill | 10% Owner | Buy | $318K (40,253 @ $7.89) |
| Nov 21, 2025 | Ab Trill | 10% Owner | Buy | $1.5M (208,872 @ $7.41) |
| Nov 21, 2025 | Jan Stahlberg | 10% Owner | Buy | $1.5M (208,872 @ $7.41) |
| Nov 20, 2025 | Ab Trill | 10% Owner | Buy | $951K (128,426 @ $7.41) |
| Nov 20, 2025 | Jan Stahlberg | 10% Owner | Buy | $951K (128,426 @ $7.41) |
| Nov 19, 2025 | Jan Stahlberg | 10% Owner | Buy | $1.7M (240,352 @ $7.21) |
| Nov 19, 2025 | Ab Trill | 10% Owner | Buy | $1.7M (240,352 @ $7.21) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.